-
Something wrong with this record ?
Multidrug resistance proteins in renal cell carcinoma
Ingrid Hodorová, Silvia Rybárová, Peter Solár, Janka Vecanová, Jozef Mihalík, P. Bohuš, Yvetta Mellová, Darina Kluchová
Language English Country Czech Republic
NLK
Free Medical Journals
from 2000
Freely Accessible Science Journals
from 2000
ProQuest Central
from 2005-01-01
Health & Medicine (ProQuest)
from 2005-01-01
ROAD: Directory of Open Access Scholarly Resources
from 2000
- MeSH
- Drug Resistance, Neoplasm MeSH
- Carcinoma, Renal Cell metabolism pathology MeSH
- Middle Aged MeSH
- Humans MeSH
- Kidney Neoplasms metabolism pathology MeSH
- ATP Binding Cassette Transporter, Subfamily B, Member 1 biosynthesis MeSH
- Multidrug Resistance-Associated Proteins biosynthesis MeSH
- Vault Ribonucleoprotein Particles antagonists & inhibitors MeSH
- Check Tag
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Female MeSH
A large number of renal cancer patients show poor or partial response to chemotherapy and the precise mechanism has not been understood yet. MDR is the principal mechanism by which many cancers develop resistance to chemotherapeutic drugs and is associated with the elevated expression of MDR proteins. These are divided into two groups: ABC transporters and non-ABC transporters. The aim of our study was to determine the expression of MDR1/Pgp, MRP1 and LRP in 47 samples of renal cell carcinomas using immunohistochemical assay. Our results were analysed in relation to nuclear grade and other clinical and pathological parameters to see the possible correlation between the expression of MDR proteins and factors mentioned above. The majority of renal carcinoma specimens showed positivity for MDR proteins. In this regard, 21 % of samples revealed positive results for MDR1, 62 % for MRP1 and 76.6 % for LRP protein. Furthermore, our study displayed significant differences between MDR1, LRP and nuclear grade. On the other hand, no association was found between MRP1 and nuclear grade, as well as between the expression of three MDR proteins and other clinically relevant parameters.
Lit.: 33
- 000
- 00000naa 2200000 a 4500
- 001
- bmc07523457
- 003
- CZ-PrNML
- 005
- 20111210135248.0
- 008
- 090518s2008 xr e eng||
- 009
- AR
- 040 __
- $a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xr
- 100 1_
- $a Hodorová, Ingrid. $7 xx0278058
- 245 10
- $a Multidrug resistance proteins in renal cell carcinoma / $c Ingrid Hodorová, Silvia Rybárová, Peter Solár, Janka Vecanová, Jozef Mihalík, P. Bohuš, Yvetta Mellová, Darina Kluchová
- 314 __
- $a Department of Anatomy, Faculty of Medicine, P. J. Šafárik University in Košice, Košice
- 504 __
- $a Lit.: 33
- 520 9_
- $a A large number of renal cancer patients show poor or partial response to chemotherapy and the precise mechanism has not been understood yet. MDR is the principal mechanism by which many cancers develop resistance to chemotherapeutic drugs and is associated with the elevated expression of MDR proteins. These are divided into two groups: ABC transporters and non-ABC transporters. The aim of our study was to determine the expression of MDR1/Pgp, MRP1 and LRP in 47 samples of renal cell carcinomas using immunohistochemical assay. Our results were analysed in relation to nuclear grade and other clinical and pathological parameters to see the possible correlation between the expression of MDR proteins and factors mentioned above. The majority of renal carcinoma specimens showed positivity for MDR proteins. In this regard, 21 % of samples revealed positive results for MDR1, 62 % for MRP1 and 76.6 % for LRP protein. Furthermore, our study displayed significant differences between MDR1, LRP and nuclear grade. On the other hand, no association was found between MRP1 and nuclear grade, as well as between the expression of three MDR proteins and other clinically relevant parameters.
- 650 _2
- $a karcinom z renálních buněk $x metabolismus $x patologie $7 D002292
- 650 _2
- $a chemorezistence $7 D019008
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a nádory ledvin $x metabolismus $x patologie $7 D007680
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a proteiny spojené s mnohočetnou rezistencí k lékům $x biosyntéza $7 D027425
- 650 _2
- $a P-glykoprotein $x biosyntéza $7 D020168
- 650 _2
- $a vault ribonucleoprotein particles $x antagonisté a inhibitory $7 D020394
- 700 1_
- $a Rybárová, Silvia, $d 1959- $7 stk2008428612
- 700 1_
- $a Solár, Peter, $d 1970- $7 xx0140463
- 700 1_
- $a Vecanová, Janka. $7 _AN032179
- 700 1_
- $a Mihalík, Jozef. $7 _AN032180
- 700 1_
- $a Bohuš, Peter $7 xx0139715
- 700 1_
- $a Mellová, Yvetta $7 xx0107607
- 700 1_
- $a Kluchová, Darina $7 xx0081799
- 773 0_
- $w MED00011004 $t Folia biologica $g Roč. 54, č. 6 (2008), s. 187-192 $x 0015-5500
- 856 41
- $u http://fb.cuni.cz/Data/files/folia_biologica/volume_54_2008_6/FB2008A0032.pdf $y plný text volně přístupný
- 910 __
- $a ABA008 $b A 970 $c 89 $y 9
- 990 __
- $a 20090518150356 $b ABA008
- 991 __
- $a 20090818110501 $b ABA008
- 999 __
- $a ok $b bmc $g 653557 $s 506845
- BAS __
- $a 3
- BMC __
- $a 2008 $b 54 $c 6 $d 187-192 $i 0015-5500 $m Folia biologica (Praha) $x MED00011004
- LZP __
- $a 2009-18/mkme